Vanguard Health Care Index Fund ETF Shares (VHT) ETF Analysis: Diversified, Low-Cost Access to U.S. Healthcare Leadership
Key Takeaways
- VHT is a passively managed exchange-traded fund (ETF) that tracks the MSCI US Investable Market Health Care 25/50 Index, holding more than 400 U.S. healthcare stocks spanning pharmaceuticals, biotechnology, medical devices, and managed care.
- The portfolio is market-cap-weighted and dominated by large-cap biopharma, led by LLY, JNJ, and ABBV.
- With a 0.09% expense ratio and a trailing dividend yield near 1.5%, VHT offers one of the lowest-cost routes to broad healthcare sector exposure.
- Over the past 30 days the fund advanced roughly 4%, while its three-month gain sits near 10%, reflecting a gradual, low-volatility uptrend rather than sharp momentum.
- Principal investment themes include obesity and metabolic drug growth, managed-care pricing, biotechnology innovation, and interest-rate-driven valuation shifts.
- For deeper technical and valuation detail, explore VHT's Price Targets and Forecast pages.
- Investors seeking systematic, data-driven ideas across sectors can review Trending AI Robots.
Vanguard Health Care ETF (VHT) Overview
VHT is a passively managed, full-replication ETF launched on January 26, 2004, and sponsored by Vanguard. Its investment objective is to track the performance of the MSCI US Investable Market Health Care 25/50 Index before fees and expenses, an index composed of large-, mid-, and small-capitalization U.S. companies classified within the healthcare sector. The fund holds roughly 420 stocks and manages assets under management (AUM) of more than $18 billion.
The portfolio is almost entirely invested in healthcare, with essentially 100% sector concentration, and is heavily tilted toward large-cap names, which account for roughly 91% of holdings. Its largest positions include Eli Lilly (LLY) at approximately 13%, Johnson & Johnson (JNJ) at about 9%, AbbVie (ABBV) near 6.5%, followed by MRK and UNH. The fund carries an expense ratio of 0.09%, among the least expensive in the healthcare category, and a beta below 1, reflecting the sector's historically defensive character.
Industry and Thematic Landscape
U.S. healthcare occupies a structurally defensive position within equity markets, with demand driven by demographics, chronic disease prevalence, and innovation rather than the business cycle. In the current environment, several themes are shaping the sector. Obesity and metabolic treatments have become a major growth engine, disproportionately benefiting the largest weight in VHT's portfolio through its top holding. Managed-care companies, meanwhile, are navigating medical cost trends and an evolving regulatory backdrop around pricing and coverage.
The macroeconomic picture adds another layer. Healthcare valuations tend to be sensitive to long-term interest rates, given the sector's mix of growth-oriented biotech and bond-like, dividend-paying large caps. Easing inflation and shifting monetary-policy expectations have supported defensive equity segments broadly, while policy debates over drug pricing continue to introduce periodic volatility across pharmaceuticals and insurers.
Performance and Positioning Snapshot
VHT has moved higher in a measured, low-volatility fashion. Over the past 30 days, the fund has risen approximately 4%, and over the trailing three months it has gained roughly 9.6%. This pattern reflects a gradual grind higher rather than a sharp, momentum-driven rally, consistent with a market-cap-weighted portfolio that leans heavily on slower-moving large-cap pharmaceutical and diversified healthcare names.
The advance has been supported by strength in the fund's largest holding, which has been a standout performer within the sector, along with relatively resilient performance across major pharmaceutical and medical-device constituents. Because the top five holdings represent a substantial share of the portfolio, their collective performance exerts an outsized influence on the ETF's overall returns, while the broad base of more than 400 names helps dampen company-specific risk.
AI Screener
Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps investors scan thousands of securities using technical indicators, fundamentals, volatility measures, AI-generated signals, market trends, price patterns, and customizable filters. The tool is designed to surface trending securities, breakout candidates, and new trading opportunities more efficiently than manual screening, while allowing users to refine results by industry, performance characteristics, and risk parameters. For investors building a healthcare-focused watchlist or monitoring sector rotation, it offers a structured, data-driven approach to idea generation. Explore the AI Screener to apply these capabilities to your own research workflow.
2026 Outlook and Key Factors to Monitor
Looking ahead, several structural factors are likely to influence VHT. The trajectory of obesity and metabolic drug adoption remains a central driver for the fund's largest holding and, by extension, the ETF's performance. Investors should also monitor the earnings cycles of major pharmaceutical and managed-care constituents, as well as developments around Medicare drug-price negotiation and broader healthcare policy.
The interest-rate environment will continue to matter. A shift toward lower rates could support the valuations of long-duration growth and biotech names, while persistently higher rates might favor the cash-generative, dividend-paying large caps that anchor the portfolio. Capital flows into sector ETFs, competitive dynamics in the low-cost healthcare fund category, and the pace of biotechnology innovation and regulatory approvals are additional variables worth watching. As a broadly diversified, market-cap-weighted vehicle, VHT's fortunes remain tied most closely to the health of its largest holdings and the broader healthcare investment cycle rather than to any single catalyst.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VHT in upward trend: price rose above 50-day moving average on October 14, 2026
VHT moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 32 of 37 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on VHT as a result. In 73 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for VHT just turned positive on October 12, 2026. Looking at past instances where VHT's MACD turned positive, the stock continued to rise in 35 of 44 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for VHT crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +2.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where VHT advanced for three days, in 253 of 311 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Aroon Indicator entered an Uptrend today. In 211 of 251 cases where VHT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 84%.
Bearish Trend Analysis
The 10-day RSI Indicator for VHT moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 36 similar instances where the indicator moved out of overbought territory. In 29 of the 36 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 52 of 72 cases where VHT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 72%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VHT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
VHT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement